347 related articles for article (PubMed ID: 31048683)
1. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.
Cocciardi S; Dolnik A; Kapp-Schwoerer S; Rücker FG; Lux S; Blätte TJ; Skambraks S; Krönke J; Heidel FH; Schnöder TM; Corbacioglu A; Gaidzik VI; Paschka P; Teleanu V; Göhring G; Thol F; Heuser M; Ganser A; Weber D; Sträng E; Kestler HA; Döhner H; Bullinger L; Döhner K
Nat Commun; 2019 May; 10(1):2031. PubMed ID: 31048683
[TBL] [Abstract][Full Text] [Related]
2.
Höllein A; Meggendorfer M; Dicker F; Jeromin S; Nadarajah N; Kern W; Haferlach C; Haferlach T
Blood Adv; 2018 Nov; 2(22):3118-3125. PubMed ID: 30455361
[TBL] [Abstract][Full Text] [Related]
3. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
Simonetti G; Mengucci C; Padella A; Fonzi E; Picone G; Delpino C; Nanni J; De Tommaso R; Franchini E; Papayannidis C; Marconi G; Pazzaglia M; Perricone M; Scarpi E; Fontana MC; Bruno S; Tebaldi M; Ferrari A; Bochicchio MT; Ghelli Luserna Di Rorà A; Ghetti M; Napolitano R; Astolfi A; Baldazzi C; Guadagnuolo V; Ottaviani E; Iacobucci I; Cavo M; Castellani G; Haferlach T; Remondini D; Capozzi F; Martinelli G
Leukemia; 2021 Oct; 35(10):2813-2826. PubMed ID: 34193978
[TBL] [Abstract][Full Text] [Related]
4. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
5. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
Loghavi S; DiNardo CD; Furudate K; Takahashi K; Tanaka T; Short NJ; Kadia T; Konopleva M; Kanagal-Shamanna R; Farnoud NR; Pierce S; Khoury JD; Jorgensen JL; Patel KP; Daver N; Yilmaz M; Medeiros LJ; Kantarjian H; Ravandi F; Wang SA
Br J Haematol; 2021 Mar; 192(6):1054-1063. PubMed ID: 33618432
[TBL] [Abstract][Full Text] [Related]
7. Genetic biomarkers identify a subgroup of high-risk patients within low-risk
Carbonell D; Suárez-González J; Chicano M; Andrés-Zayas C; Díez-Díez M; Rodríguez-Macías G; Muñiz P; Kwon M; Anguita J; Díez-Martín JL; Buño I; Martínez-Laperche C
Leuk Lymphoma; 2021 May; 62(5):1178-1186. PubMed ID: 33372822
[TBL] [Abstract][Full Text] [Related]
8. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
Kansal R
Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
[TBL] [Abstract][Full Text] [Related]
9. NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
Zhao D; Zarif M; Eladl E; Capo-Chichi JM; Smith AC; Atenafu EG; Tierens A; Minden MD; Schuh A; Chang H
Leuk Res; 2022 Jul; 118():106869. PubMed ID: 35636054
[TBL] [Abstract][Full Text] [Related]
10. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
Shi Y; Xue Y; Wang C; Yu L
Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
[TBL] [Abstract][Full Text] [Related]
11. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.
Krönke J; Bullinger L; Teleanu V; Tschürtz F; Gaidzik VI; Kühn MW; Rücker FG; Holzmann K; Paschka P; Kapp-Schwörer S; Späth D; Kindler T; Schittenhelm M; Krauter J; Ganser A; Göhring G; Schlegelberger B; Schlenk RF; Döhner H; Döhner K
Blood; 2013 Jul; 122(1):100-8. PubMed ID: 23704090
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia.
Chen X; Zhu H; Qiao C; Zhao S; Liu L; Wang Y; Jin H; Qian S; Wu Y
Hematology; 2021 Dec; 26(1):111-122. PubMed ID: 33491606
[TBL] [Abstract][Full Text] [Related]
13. Myeloid sarcoma with
Ramia de Cap M; Wu LP; Hirt C; Pihan GA; Patel SS; Tam W; Bueso-Ramos CE; Kanagal-Shamanna R; Raess PW; Siddon A; Narayanan D; Morgan EA; Pinkus GS; Mason EF; Hsi ED; Rogers HJ; Toth L; Foucar K; Hurwitz SN; Bagg A; Rets A; George TI; Orazi A; Arber DA; Hasserjian RP; Weinberg OK;
Leuk Lymphoma; 2023 May; 64(5):972-980. PubMed ID: 36960680
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Minimal Residual Disease in Standard-Risk AML.
Ivey A; Hills RK; Simpson MA; Jovanovic JV; Gilkes A; Grech A; Patel Y; Bhudia N; Farah H; Mason J; Wall K; Akiki S; Griffiths M; Solomon E; McCaughan F; Linch DC; Gale RE; Vyas P; Freeman SD; Russell N; Burnett AK; Grimwade D;
N Engl J Med; 2016 Feb; 374(5):422-33. PubMed ID: 26789727
[TBL] [Abstract][Full Text] [Related]
15. NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features.
Andersen MT; Andersen MK; Christiansen DH; Pedersen-Bjergaard J
Leukemia; 2008 May; 22(5):951-5. PubMed ID: 18273044
[TBL] [Abstract][Full Text] [Related]
16. Mutational spectrum of
Pettersson L; Holmgren B; Juliusson G; Lazarevic VL; Ehinger M
Leuk Lymphoma; 2021 Aug; 62(8):1958-1966. PubMed ID: 33711909
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
[TBL] [Abstract][Full Text] [Related]
18. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.
Quesada AE; Montalban-Bravo G; Luthra R; Patel KP; Sasaki K; Bueso-Ramos CE; Khoury JD; Routbort MJ; Bassett R; Hidalgo-Lopez JE; Zhao C; Lin P; Loghavi S; Ok CY; Kadia T; DiNardo CD; Kantarjian H; Garcia-Manero G; Kanagal-Shamanna R
Mod Pathol; 2020 Sep; 33(9):1678-1689. PubMed ID: 32238878
[TBL] [Abstract][Full Text] [Related]
20. Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration.
Cappelli LV; Meggendorfer M; Baer C; Nadarajah N; Hutter S; Jeromin S; Dicker F; Kern W; Haferlach T; Haferlach C; Höllein A
Leukemia; 2022 Feb; 36(2):394-402. PubMed ID: 34376804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
